Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Rogaratinib × Genitourinary × Clear all

Phase

Phase 2 2 Phase 1 2 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 8 Docetaxel 8 Magnetic Resonance Spectroscopy 6 Androgen Antagonists 6 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5 Cisplatin 5 gallium 68 PSMA-11 4 Radiosurgery 4 Prednisone 4 Leuprolide 4 Goserelin 4 Carboplatin 4 luprolide acetate gel depot 3 enzalutamide 3 bicalutamide 3 Triptorelin Pamoate 3 Celecoxib 3 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3 valrubicin 2 pembrolizumab 2 cabazitaxel 2 Zoledronic Acid 2 Vinblastine 2 Specimen Handling 2 Nivolumab 2 Mitoxantrone 2 Mitomycin 2 Methotrexate 2 Interferon-alpha 2 Immunoglobulin G 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03410693 2022-09-28

FORT-1

Bayer

Phase 2/3 Completed

175 enrolled 19 charts

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡